- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on May 10, 2013
b3c newswire
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
>Batavia Bioservices and UvA Holding Announce STEP? Technology Exclusive License
>Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing
>Haselmeier Establishes Haselmeier Inc. in the United States
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
>Batavia Bioservices and UvA Holding Announce STEP? Technology Exclusive License
>Acumen Pharmaceuticals Inc. Announces First Close of Series A Financing
>Haselmeier Establishes Haselmeier Inc. in the United States
BioSpace
>CytRx Corporation Ditches Lung Cancer Drug After Phase 2 Trial Failure
>The Next Billionaire: A Statistician Who Changed Medicine
>University of Reading Scientists Reveal Drinking Champagne Could Improve Memory
>Could Eating Peppers Prevent Parkinson's? University of Washington Study
>Soy and Tomato May Be Effective in Preventing Prostate Cancer, University of Illinois Study
>CytRx Corporation Ditches Lung Cancer Drug After Phase 2 Trial Failure
>The Next Billionaire: A Statistician Who Changed Medicine
>University of Reading Scientists Reveal Drinking Champagne Could Improve Memory
>Could Eating Peppers Prevent Parkinson's? University of Washington Study
>Soy and Tomato May Be Effective in Preventing Prostate Cancer, University of Illinois Study
BioSpace - Breaking News
>Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in /i>
>Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
>Izun Pharmaceuticals Initiates Additional Oral Mucositis Trial Sites
>Merck & Co., Inc., GlaxoSmithKline Reduce HPV Vaccine Prices by 95 Pct. in Poorest Regions
>Cipla Ltd. Probed for Anti-Competitive Practices
>Acorda Therapeutics Announces Data Showing Dalfampridine Improves Motor Function in Preclinical Model of Post-Stroke Deficits Published in /i>
>Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
>Izun Pharmaceuticals Initiates Additional Oral Mucositis Trial Sites
>Merck & Co., Inc., GlaxoSmithKline Reduce HPV Vaccine Prices by 95 Pct. in Poorest Regions
>Cipla Ltd. Probed for Anti-Competitive Practices
Biotech News - Business Wire
>Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
>Cancer Genetics Announces Conference Call to Discuss First Quarter Results
>Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
>Louisiana Continuing Care Hospital Launches Xenex's Infection Protection Robot
>Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
>Cancer Genetics Announces Conference Call to Discuss First Quarter Results
>Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
>Louisiana Continuing Care Hospital Launches Xenex's Infection Protection Robot
Biotech News - PR Newswire
>Geisinger Partners With Indivumed for Personalized Medicine Initiative
>14. Internationaler Workshop für medizinische Ausbildung zum Thema zielgerichtete Molekulartherapie bei Krebs (MTTC)
>L'Atelier international de formation médicale sur les thérapies moléculaires ciblées du cancer (TMCC) à sa 14e édition
>Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
>Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
>Geisinger Partners With Indivumed for Personalized Medicine Initiative
>14. Internationaler Workshop für medizinische Ausbildung zum Thema zielgerichtete Molekulartherapie bei Krebs (MTTC)
>L'Atelier international de formation médicale sur les thérapies moléculaires ciblées du cancer (TMCC) à sa 14e édition
>Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
>Canada's Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
Burrill Report
>What Transparency Means for Healthcare
>Spate of Life Science IPOs Ready to Debut
>Healthcare Spending Projections May Be Overstated by $770B
>Celgene Strikes A Deal with Concert
>The May 2013 Issue of The Burrill Report
>What Transparency Means for Healthcare
>Spate of Life Science IPOs Ready to Debut
>Healthcare Spending Projections May Be Overstated by $770B
>Celgene Strikes A Deal with Concert
>The May 2013 Issue of The Burrill Report
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
Clinical Trials - Business Wire
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Clinical Trials - PR Newswire
>Uroplasty Announces STEP Study 3-Year Results Demonstrate Sustained Therapeutic Effects Of Percutaneous Tibial Nerve Stimulation
>Die Celladon Corporation und SIRO Clinpharm kündigen Präsentation auf der "Statisticians in the Pharmaceutical Industry International Conference" an
>Shire Wins Patent Trial Against Watson Concerning LIALDA®
>New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial
>Dr. Keith Ablow Conducts Study for Electronic Cigarette Effectiveness
>Uroplasty Announces STEP Study 3-Year Results Demonstrate Sustained Therapeutic Effects Of Percutaneous Tibial Nerve Stimulation
>Die Celladon Corporation und SIRO Clinpharm kündigen Präsentation auf der "Statisticians in the Pharmaceutical Industry International Conference" an
>Shire Wins Patent Trial Against Watson Concerning LIALDA®
>New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The PROTECT AF Trial
>Dr. Keith Ablow Conducts Study for Electronic Cigarette Effectiveness
CNN Top Stories
>Tiger moms turning kids into robots
>Gay rights vs. immigration reform
>One way to help homeless moms
>Suspect's DNA test is done
>Teen gets 27 years in Mississippi killing
>Tiger moms turning kids into robots
>Gay rights vs. immigration reform
>One way to help homeless moms
>Suspect's DNA test is done
>Teen gets 27 years in Mississippi killing
Contract Pharma
>Financial Report: Anacor Pharmaceuticals
>Financial Report: PDL BioPharma
>Adaptive Bio, BMS In Biomarker Discovery Pact
>Financial Report: Ligand
>OsoBio Names Quality VP
>Financial Report: Anacor Pharmaceuticals
>Financial Report: PDL BioPharma
>Adaptive Bio, BMS In Biomarker Discovery Pact
>Financial Report: Ligand
>OsoBio Names Quality VP
FDA Drugs- What's New
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
>Funding and Support
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
>Funding and Support
FDA News - Business Wire
>Cytori Reports First Quarter 2013 Business and Financial Results
>SARTA MedStart Progress Report Identifies 18 New Med Tech Companies
>CA Technologies Declares Quarterly Dividend
>NEC Display Solutions Receives FDA 510(k) Clearance on MD211C2 and MD211C3 Medical Diagnostic Monitors
>BioCryst to Present at Two Upcoming Investor Conferences
>Cytori Reports First Quarter 2013 Business and Financial Results
>SARTA MedStart Progress Report Identifies 18 New Med Tech Companies
>CA Technologies Declares Quarterly Dividend
>NEC Display Solutions Receives FDA 510(k) Clearance on MD211C2 and MD211C3 Medical Diagnostic Monitors
>BioCryst to Present at Two Upcoming Investor Conferences
FDA Press Releases
>FDA alerts health care providers of lack of sterility assurance of drug products from The Compounding Shop
>FDA issues proposal to increase consumer awareness of tanning bed risks
>FDA warns pregnant women to not use certain migraine prevention medicines
>FDA approves Plan B One-Step emergency contraceptive without a prescription for women 15 years of age and older
>FDA approves Procysbi for rare genetic condition
>FDA alerts health care providers of lack of sterility assurance of drug products from The Compounding Shop
>FDA issues proposal to increase consumer awareness of tanning bed risks
>FDA warns pregnant women to not use certain migraine prevention medicines
>FDA approves Plan B One-Step emergency contraceptive without a prescription for women 15 years of age and older
>FDA approves Procysbi for rare genetic condition
FDA Vaccines, Blood and Biologics - What's New
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
>Public Workshop: Statistical Process Controls for Blood Establishments - Transcripts
>Draft Agenda - Day 1
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
>Public Workshop: Statistical Process Controls for Blood Establishments - Transcripts
>Draft Agenda - Day 1
FierceBiotech
>Pain Therapeutics, Durect shares nosedive on haziness for Pfizer's Remoxy
>Anna Protopapas replaces Deborah Dunsire as Millennium oncology head
>Eli Lilly jettisons cancer contender after another Phase III failure
>Biotech VC firm Frazier Healthcare closes in on $300M fund
>Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups
>Pain Therapeutics, Durect shares nosedive on haziness for Pfizer's Remoxy
>Anna Protopapas replaces Deborah Dunsire as Millennium oncology head
>Eli Lilly jettisons cancer contender after another Phase III failure
>Biotech VC firm Frazier Healthcare closes in on $300M fund
>Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups
FierceBiotech IT
>GlaxoSmithKline exec details expectations for online clinical trial research
>Hong Kong billionaire backs Big Data effort in biomedicine at Oxford University
>Pfizer opts to keep running Accelrys software in its labs
>GlaxoSmithKline 'listened' to social media chatter about vaccine worries
>Doc launches user-friendly website for clinical trials searches
>GlaxoSmithKline exec details expectations for online clinical trial research
>Hong Kong billionaire backs Big Data effort in biomedicine at Oxford University
>Pfizer opts to keep running Accelrys software in its labs
>GlaxoSmithKline 'listened' to social media chatter about vaccine worries
>Doc launches user-friendly website for clinical trials searches
FierceBiotech Research
>Genetic 'switch' could halt aggressive cancer growth
>Inhibiting a protein could provide new avenue for antidepressant drug development
>Scientists create more accurate animal model of Type 2 diabetes
>New molecule could be potential therapy for muscular dystrophy
>Mayo Clinic develops drug that stops growth of kidney cancer
>Genetic 'switch' could halt aggressive cancer growth
>Inhibiting a protein could provide new avenue for antidepressant drug development
>Scientists create more accurate animal model of Type 2 diabetes
>New molecule could be potential therapy for muscular dystrophy
>Mayo Clinic develops drug that stops growth of kidney cancer
FiercePharma
>AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value
>Amgen forges Chinese JV for Vectibix
>WSJ: J&J federal Risperdal deal hung up on language over breasts
>Behold the patent cliff: U.S. drug market shrinks for first time
>Dendreon's Provenge sales disappoint once again with 17% decline
>AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value
>Amgen forges Chinese JV for Vectibix
>WSJ: J&J federal Risperdal deal hung up on language over breasts
>Behold the patent cliff: U.S. drug market shrinks for first time
>Dendreon's Provenge sales disappoint once again with 17% decline
FiercePharma Manufacturing
>New Jersey looks to law that would allow unused drugs to be donated
>Sale of plant to Novartis doesn't reverse Dendreon's ill fortunes
>Pediatric drug shortages draw Congressional attention
>Hamburg faces Senate as new compounding regulations progress
>Proposed law would delay unit drug tracking for 15 years
>New Jersey looks to law that would allow unused drugs to be donated
>Sale of plant to Novartis doesn't reverse Dendreon's ill fortunes
>Pediatric drug shortages draw Congressional attention
>Hamburg faces Senate as new compounding regulations progress
>Proposed law would delay unit drug tracking for 15 years
FierceVaccines
>CDC continues to build defenses in H7N9 lull
>GSK, Merck agree on HPV vax discount with GAVI
>Heroin vaccine keeps rats clean
>GSK anonymously listens to online vax talk, then mines data for nuggets
>Takeda takes on Sanofi with $250M dengue buyout
>CDC continues to build defenses in H7N9 lull
>GSK, Merck agree on HPV vax discount with GAVI
>Heroin vaccine keeps rats clean
>GSK anonymously listens to online vax talk, then mines data for nuggets
>Takeda takes on Sanofi with $250M dengue buyout
Health News - BizJournals.com
>Trice Ortho raises $3M, names president
>The 'scoop? of Quintiles? market debut
>Insurance exec sees rate spike under health reform
>Brian Druker explains how tanning kills
>Discovery Labs to sell more stock
>Trice Ortho raises $3M, names president
>The 'scoop? of Quintiles? market debut
>Insurance exec sees rate spike under health reform
>Brian Druker explains how tanning kills
>Discovery Labs to sell more stock
Health News - CNBC
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
Inside Industry - Gen
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
>Forest Labs Bets Up To $460M on Trevena Heart Failure Drug
>Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
>Forest Labs Bets Up To $460M on Trevena Heart Failure Drug
>Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
Marketwire - Pharma and Biotech
>Applied DNA Sciences to Host Conference Call Thursday, May 16, 2013
>Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
>West Announces Third-Quarter 2013 Dividend
>Horizon Pharma Announces First Quarter 2013 Financial Results and Provides Business Update
>Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence
>Applied DNA Sciences to Host Conference Call Thursday, May 16, 2013
>Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
>West Announces Third-Quarter 2013 Dividend
>Horizon Pharma Announces First Quarter 2013 Financial Results and Provides Business Update
>Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dependence
MassBio News
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
Medical Pharma - PR Newswire
>Maxim Healthcare Services Names National Caregiver of the Year Winner
>Lupus Research Institute and the S.L.E. Lupus Foundation Address Global Treatment Issues for World Lupus Awareness Day
>Premium Online Content Added to the ARTHRO Mentor? Training Curriculum
>Boston Scientific Receives CE Mark Approval For The Rhythmia? Mapping System
>Allied Healthcare Products Reports Loss On Depressed Sales
>Maxim Healthcare Services Names National Caregiver of the Year Winner
>Lupus Research Institute and the S.L.E. Lupus Foundation Address Global Treatment Issues for World Lupus Awareness Day
>Premium Online Content Added to the ARTHRO Mentor? Training Curriculum
>Boston Scientific Receives CE Mark Approval For The Rhythmia? Mapping System
>Allied Healthcare Products Reports Loss On Depressed Sales
National Center for Biotechnology Information
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
Nature Biotechnology
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
New York Times- Biotechnology
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
>Deal Possible for Life Technologies
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
>Deal Possible for Life Technologies
New York Times- Pharmaceuticals
>Generic Biotech Drugs
>Living With Cancer: Good News Soup
>Promising Alzheimer’s Treatment Fails, Drug Maker Says
>Pfizer Turning to the Internet to Sell Viagra
>To Fight Pandemics, Reward Research
>Generic Biotech Drugs
>Living With Cancer: Good News Soup
>Promising Alzheimer’s Treatment Fails, Drug Maker Says
>Pfizer Turning to the Internet to Sell Viagra
>To Fight Pandemics, Reward Research
OnBioVC
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
Outsourcing-Pharma
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
>Changes to EU clinical trial laws will mean fairer playing field, says Clinipace
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
>Changes to EU clinical trial laws will mean fairer playing field, says Clinipace
Pharma News - Business Wire
>Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
>Research and Markets: Neuromodulation Market Research Report Forecasts to 2017 - Neuromodulation emerging as one of the fastest growing segments of the medical device market
>Acceleron's ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
>Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
>Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain
>Research and Markets: Neuromodulation Market Research Report Forecasts to 2017 - Neuromodulation emerging as one of the fastest growing segments of the medical device market
>Acceleron's ACE-536 Preclinical Data Presentation Selected for Best Abstract at 12th International Symposium on Myelodysplastic Syndromes
>Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
Pharma News - PharmiWeb
>Takeda Appoints New President for Millennium: The Takeda Oncology Company
>Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes
>GSK and Save the Children form unique partnership to save the lives of one million children
>Arthritis Foundation Launches Public Awareness Campaign To Dispel Myths About Arthritis
>EMD Millipore Launches OsteoMAX-XF?, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium
>Takeda Appoints New President for Millennium: The Takeda Oncology Company
>Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes
>GSK and Save the Children form unique partnership to save the lives of one million children
>Arthritis Foundation Launches Public Awareness Campaign To Dispel Myths About Arthritis
>EMD Millipore Launches OsteoMAX-XF?, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium
Pharma News - PR Newswire
>The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
>Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
>ChromaDex® Reports Results for the First Quarter 2013
>Shelia Barchuk Named a VIP Member of Worldwide Who's Who for Excellence in Business Management
>The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
>Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
>Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
>ChromaDex® Reports Results for the First Quarter 2013
>Shelia Barchuk Named a VIP Member of Worldwide Who's Who for Excellence in Business Management
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
PR Leap - Biotech
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
>Vivante GMP Solutions Announces Expansion of Technical Staff
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
>Vivante GMP Solutions Announces Expansion of Technical Staff
PRWeb - Biotechnology
>MarketResearch.com Announces the Release of New Report Called The...
>BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform...
>Wysebridge Patent Bar Review Supports the National Foundation for...
>New Thermal Controller with User-Friendly PC Software
>New Analysis Yields Improvements in Classic 3D Imaging Technique
>MarketResearch.com Announces the Release of New Report Called The...
>BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform...
>Wysebridge Patent Bar Review Supports the National Foundation for...
>New Thermal Controller with User-Friendly PC Software
>New Analysis Yields Improvements in Classic 3D Imaging Technique
PRWeb - Pharmaceuticals
>NSG's New FUV Absorbance Standard Series for UV/VIS Spectrometer...
>Physician Resource Management Announces Oncology Alliance With Axium...
>Globiox Inc. and Sparta Systems Announce TrackWise®...
>R.M.S.S Now Offering Reeferman Medical Marijuana Seeds
>Transvaginal Mesh Lawyers at Bernstein Liebhard LLP Note Issuance of...
>NSG's New FUV Absorbance Standard Series for UV/VIS Spectrometer...
>Physician Resource Management Announces Oncology Alliance With Axium...
>Globiox Inc. and Sparta Systems Announce TrackWise®...
>R.M.S.S Now Offering Reeferman Medical Marijuana Seeds
>Transvaginal Mesh Lawyers at Bernstein Liebhard LLP Note Issuance of...
Scientific American
>Mercury in Seafood Diet Linked to Fox Die-Off
>Quantum Meld Brings Photons Together
>Physics Gets Frothy as Mathematicians Dissect Mister Bubble [Video]
>Valley Fever Throws Baseball a Curve
>Hanford Nuclear Waste Cleanup Plant May Be Too Dangerous
>Mercury in Seafood Diet Linked to Fox Die-Off
>Quantum Meld Brings Photons Together
>Physics Gets Frothy as Mathematicians Dissect Mister Bubble [Video]
>Valley Fever Throws Baseball a Curve
>Hanford Nuclear Waste Cleanup Plant May Be Too Dangerous
Sports - ESPN Basketball
>Judge tosses ex-Miami coach Haith's petition
>NCAA hoops panel: More replay, charge fix
>Rutgers to keep playing Seton Hall after move
>Coaches push for changes to transfer rule
>Gordon to leave Arizona State, Sendek says
>Judge tosses ex-Miami coach Haith's petition
>NCAA hoops panel: More replay, charge fix
>Rutgers to keep playing Seton Hall after move
>Coaches push for changes to transfer rule
>Gordon to leave Arizona State, Sendek says
Sports News - ESPN
>Ex-Ga. Tech WR Greene to walk on at Ohio St.
>Oklahoma State QB Lunt decides to transfer
>Ex-Buffs QB Hirschman to transfer to Akron
>Columbia responds to report of racist tweets
>Checking the trends with Notre Dame, non-AQ programs
>Ex-Ga. Tech WR Greene to walk on at Ohio St.
>Oklahoma State QB Lunt decides to transfer
>Ex-Buffs QB Hirschman to transfer to Akron
>Columbia responds to report of racist tweets
>Checking the trends with Notre Dame, non-AQ programs
Xconomy Life Sciences
>East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More
>Dunsire Out At Millennium/Takeda, Replaced by Anna Protopapas
>Rockwell Medical Set to Disrupt Dialysis With New Drugs, DaVita Deal
>Dendreon Shares Fall Again, as Provenge Sales Slump
>Domain Associates, Regado Bet Big on Heart Drug
>East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More
>Dunsire Out At Millennium/Takeda, Replaced by Anna Protopapas
>Rockwell Medical Set to Disrupt Dialysis With New Drugs, DaVita Deal
>Dendreon Shares Fall Again, as Provenge Sales Slump
>Domain Associates, Regado Bet Big on Heart Drug
Yahoo Biotech News
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)